Open AccessCOVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) – A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergo
Author(s) -
Oliver Pfaar,
Ludger Klimek,
Eckard Hamelmann,
Jörg Kleine-Tebbe,
Christian Taube,
Martin Wagenmann,
Thomas Werfel,
Randolf Brehler,
Natalija Novak,
Norbert Mülleneisen,
Sven Becker,
Margitta Worm
Publication year - 2021
Publication title -
allergologie select
Language(s) - English
Resource type - Journals
ISSN - 2512-8957
DOI - 10.5414/alx02241e
Subject(s) - german , medicine , vaccination , allergy , immunology , position paper , covid-19 , clinical immunology , antibody , inflammation , pathology , disease , archaeology , infectious disease (medical specialty) , history
After the beginning and during the worldwide pandemic caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), patients with allergic and atopic diseases have felt and still feel insecure. Currently, four vaccines against SARS-CoV-2 have been approved by the Paul Ehrlich Institute in Germany, and vaccination campaigns have been started nationwide. In this respect, it is of utmost importance to give recommendations on possible immunological interactions and potential risks of immunomodulatory substances (monoclonal antibodies, biologicals) during concurrent vaccination with the approved vaccines.